<DOC>
	<DOCNO>NCT00897312</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer , hepatitis C , Crohn disease laboratory may help doctor learn change occur DNA identify biomarkers related cancer disease . PURPOSE : This laboratory study look effect biological therapy biomarkers patient untreated hepatitis C , metastatic melanoma , Crohn disease .</brief_summary>
	<brief_title>Effect Biological Therapy Biomarkers Patients With Untreated Hepatitis C , Metastatic Melanoma , Crohn Disease</brief_title>
	<detailed_description>OBJECTIVES : - To determine variety immune-modulating therapy ( i.e. , interferon alfa [ IFN-α ] patient untreated acute chronic hepatitis C , anti-tumor necrosis factor patient active inflammatory bowel disease ( i.e. , Crohn disease ) , anticytotoxic T-lymphocyte antigen immunoglobulin patient metastatic melanoma ) affect tissue expression indoleamine 2 , 3 dioxygenase ( IDO ) , major immune-regulatory mechanism . - To determine whether administration pegylated INF-α patient untreated acute chronic hepatitis C cause systemic change IDO pathway , indicate lower serum tryptophan ( TRP ) elevate serum kynurenine ( KYN ) . - To determine whether administration ticilimumab ( i.e. , anti-CTLA4 human monoclonal antibody CP-675,206 ) patient metastatic melanoma inhibits activation IDO pathway indicate normal serum TRP normal serum KYN . - To determine whether administration infliximab patient Crohn disease inhibit activation IDO pathway , indicate normal serum TRP normal serum KYN . OUTLINE : Serum sample collect patient hepatitis C metastatic melanoma baseline 3 4 week treatment initiate . Previously collect sample patient Crohn disease also assess time point . Samples analyze tryptophan kynurenine level via high-performance liquid chromatography . PROJECTED ACCRUAL : A total 15 patient untreated acute chronic Hepatitis C , 15 patient metastatic melanoma , 20 patient Crohn disease accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute chronic hepatitis C Receiving pegylated interferon alfa ribavirin Metastatic melanoma Receiving ticilimumab Crohn disease Received prior infliximab Not specify PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>hepatitis C infection</keyword>
	<keyword>melanoma ( skin )</keyword>
	<keyword>precancerous/nonmalignant condition</keyword>
</DOC>